On May 13, the Plasma Protein Therapeutics Association hosted its annual Congressional Fly-In, preceded by its inaugural Rooftop Reception in Washington, D.C. The events brought together PPTA member companies, patient advocacy organizations, and industry stakeholders to educate members of Congress about the unique nature of plasma-derived therapies and the patients who rely on them every day.
The Rooftop Reception, held the evening before the Fly-In, welcomed around 60 attendees for the opportunity to connect and discuss shared advocacy priorities ahead of meetings on Capitol Hill. Welcome remarks were delivered by PPTA President and CEO Anita Brikman and GBS|CIDP Foundation International President and CEO Lisa Butler, both of whom highlighted the importance of collaboration between industry and patient communities to support patient access to plasma-derived therapies.
The Congressional Fly-In began the following morning with a welcome breakfast and advocacy overview led by PPTA Vice President of Government Affairs Sharon Pearce and Director of Government Relations Branden Cordeiro. Participants received updates on key policy priorities and messaging before heading to Capitol Hill for meetings with lawmakers and congressional staff.
.jpg)
The event drew strong participation from patient advocacy organizations and PPTA member companies. In total, 30 participants joined PPTA in Washington, including representatives from organizations such as Hemophilia Federation of America, Alpha-1 Foundation, Immune Deficiency Foundation, and GBS|CIDP Foundation International.
PPTA teams met with 26 congressional offices in both the U.S. House of Representatives and Senate to discuss the importance of policies that support patient access to plasma-derived therapies. Conversations focused on several key messages, including the unique nature of plasma-derived therapies compared to traditional drugs and biologics, the importance of ensuring patients can access the specific therapies prescribed by their physicians, and the need to support a stable and resilient plasma ecosystem.
Meetings also reinforced the critical role plasma-derived therapies play for individuals living with rare and chronic conditions, and the importance of continued engagement with policymakers on issues impacting patient access and supply reliability.
PPTA will continue working alongside member companies, patient advocates, and stakeholders to educate policymakers and advance awareness of the plasma-derived therapies community and the patients these therapies serve.
.jpg)